SENSEX NIFTY
Apr 01, 2013, 10.51 AM IST | Source: Reuters

Dr Reddy's shares gain on Zenatane launch

Shares in Dr.Reddy's Laboratories gain 2.1 percent after the company on Thursday said in a statement that it launched Zenatane, a generic version of Accutane drug, following its approval by the United States Food & Drug Administration.

Dr Reddy's shares gain on Zenatane launch

Shares in Dr.Reddy's Laboratories gain 2.1 percent after the company on Thursday said in a statement that it launched Zenatane, a generic version of Accutane drug, following its approval by the United States Food & Drug Administration.

The company added that the drug had USD 309 million in sales for the most recent twelve months ending January 2013, according to IMS Health.

"Assuming an incremental 20-25 percent price drop and 20 percent market share, this could be USD 50 million per year revenue opportunity for Dr.Reddy's," Morgan Stanley said in a report.

Dr Reddys Labs stock price

On July 28, 2014, Dr Reddys Laboratories closed at Rs 2766.70, up Rs 20.85, or 0.76 percent. The 52-week high of the share was Rs 2939.80 and the 52-week low was Rs 2025.00.


The company's trailing 12-month (TTM) EPS was at Rs 113.47 per share as per the quarter ended March 2014. The stock's price-to-earnings (P/E) ratio was 24.38. The latest book value of the company is Rs 547.69 per share. At current value, the price-to-book value of the company is 5.05.

READ MORE ON  Dr.Reddy's Laboratories
Set email alert for

ADS BY GOOGLE

video of the day

Positive on PSU banks; NPA cycle may have peaked: Barclays

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.